Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...
emjreviews.com8h
Neoadjuvant T-VEC Shows Promise for Difficult-to-Treat Basal Cell Carcinoma
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
The Scotsman11d
Woman who lost leg to cancer and given six months to live marries husband
This is the heart-wrenching moment a bride given less than six months to live after losing her leg to cancer made it down the aisle to marry her partner - during one of their two weddings.
Sussex Express11d
Woman who lost leg to cancer and given six months to live marries husband
This is the heart-wrenching moment a bride given less than six months to live after losing her leg to cancer made it down the aisle to marry her partner - during one of their two weddings. Did you ...